

Intended Use

For the *in vitro* quantitative kinetic determination of lactate dehydrogenase activity in serum.

Clinical Significance

Increased levels of LD are associated with myocardial infarction. Levels reach a maximum approximately 48 hours after the onset of pain and persist about ten days. The degree of elevation is of value in assessing the extent of damage and in developing a prognosis. LD elevations are also observed in liver disease, pernicious anemia, in some cases of renal disease, and in some cases of skeletal muscle trauma.¹

Method History

Wroblewski and Ladue² published the first UV kinetic method for the determination of LDH activity in serum in 1955. Their method was based on the classic Kubowitz and Ott³ assay (1943) utilizing the pyruvate to lactate reaction. In 1956, Wacker et al⁴ described a procedure that followed a lactate to pyruvate reaction. The lactate to pyruvate reaction became the preferred reaction⁵, even though the slower of the two, because of a wider linear range⁶ and no pre-incubation requirement⁷. The present method follows the forward reaction and has been optimized for greater sensitivity and linearity as outlined by Gay et al.⁸

Principle



Lactate dehydrogenase catalyzes the oxidation of lactate to pyruvate with simultaneous reduction of NAD to NADH. The rate of NAD reduction can be measured as an increase in absorbance at 340nm. This rate is directly proportional to LD activity in serum.

Reagent Composition

After combining R1 and R2 the reagent contains: NAD 7.5 mM, L-Lactate 55 mM, Buffer pH 8.95. Non-reactive stabilizers and sodium azide (0.1%) as preservative.

Reagent Preparation

Reagents are supplied as ready to use liquids. To prepare a working reagent, mix 5 parts Buffer (R1) with 1 part Co-enzyme (R2).

Reagent Storage and Stability

Reagents are stable until stated expiration if stored as directed. Working reagent is stable 14 days when stored at 2-8°C. Protect from light. Avoid microbial contamination.

Precautions

1. This reagent is for *in vitro* diagnostic use only.
2. The reagents contain sodium azide (0.1%) as a preservative. Do not ingest. Avoid skin and eye contact. Sodium azide may react with lead and copper plumbing fixtures giving rise to explosive metal azides. Flush with large volumes of water when disposing of the reagent.
3. All specimens and controls should be handled in accordance with good laboratory practices using appropriate precautions as described in the CDC/NIH Manual, "Biosafety in Microbiological and Biomedical Laboratories," 2nd ed., 1988, HHS Publication No. (CDC) 88-8395.

Specimen Collection and Storage

1. Non-hemolyzed serum is recommended. Red cells contain large concentrations of LD.⁵
2. The serum should be removed from the clot promptly.
3. Samples should be assayed soon after collection. LD in serum is reported stable for two to three days at room temperature.⁹
4. Do not freeze or expose the serum to high temperatures (37°C) as this may inactivate thermolabile LD isoenzymes.¹⁰
5. Specimen collection should be carried out in accordance with NCCLS M29-T2.¹¹ No method can offer complete assurance that human blood samples will not transmit infection. Therefore, all samples should be considered potentially infectious.

Interferences

1. Certain drugs and substances affect LD activity. See Young, et al.¹²
2. Bilirubin to the level of 20 mg/dl has been found to exhibit negligible interference ($\leq 5\%$) in this assay.
3. Hemolysis has been shown to significantly interfere with the assay at levels as low as 100 mg/dl.

Materials Provided

Lactate Dehydrogenase Buffer (R1) Reagent
Lactate Dehydrogenase Co-Enzyme (R2) Reagent

Materials Required but not Provided

1. Accurate pipetting devices. (1.0ml and 50ul)
2. Test tubes/rack
3. Timer. (To measure 30 second and one minute intervals.)
4. Heating bath or block (37°C).
5. Spectrophotometer able to read at 340 nm (UV).
6. Controls to monitor the validity of the reaction.

Test Procedure (Automated-General)

Wavelength:	340nm
Assay Type:	Kinetic
Sample/Reagent Ratio:	1:21
Reaction Direction:	Increasing
Temperature:	37°C
Lag Time:	30 seconds
Read Time:	60 seconds
Low Normal:	80 U/L
High Normal:	285 U/L

For technical assistance concerning this product, contact the manufacturer's Technical Service Department.

Test Procedure (Manual)

1. Prepare the working reagent as directed.
2. Pipette 1.0ml of reagent into appropriate tubes and pre-warm at 37°C for five minutes.
3. Zero spectrophotometer with water at 340nm.
4. Transfer 0.050 ml (50ul) of sample to reagent, mix and return to heating block.
5. After 30 seconds, read and record absorbance (A₁ Reading). Return tube to 37°C for one minute.
6. After exactly one minute, read and record absorbance (A₂ Reading).
7. The change in absorbance (A₂-A₁) multiplied by the factor 3376 (See Calculations) will yield results in U/L.

Lactate Dehydrogenase (Liquid) Reagent Set

Note: If the spectrophotometer being used is equipped with a temperature controlled cuvette, the reaction mixture may be left in the cuvette while the absorbance readings are taken.

Limitations

1. Hemolyzed serum will cause falsely elevated serum LD levels.
2. Samples that exceed the linearity limit (1000 U/L) should be diluted with an equal volume of saline and re-assayed. Multiply the results by two to compensate for the dilution.

Calibration

The procedure is standardized by means of the millimolar absorptivity of NADH taken as 6.22 at 340nm under the test conditions described.

Quality Control

The validity of the reaction should be monitored by use of control samples with known normal and abnormal LD values. These controls should be run at least with every working shift in which LD assays are performed. It is recommended that each laboratory establish their own frequency of control determination.

Calculation

One international Unit (U/L) is defined as the amount of enzyme that catalyzes the transformation of one micromole of substrate per minute.

$$\text{IU/L} = \frac{(A_2 - A_1) \times 1.050 \times 1000}{1 \times 6.22 \times 0.050 \text{ ml}} = (A_2 - A_1) \times 3376$$

Where:

(A₂-A₁) = Change in absorbance
1.050 = Total reaction volume in ml
1000 = Conversion of U/ml to U/L
1 = Light path in cm
6.22 = Millimolar absorptivity of NADH
0.050 = Sample volume in ml

Example: If initial reading (A₁) = 0.450
Final reading (A₂) = 0.480
(A₂-A₁) = 0.03
Then 0.03 x 3376 = 101 U/L

Note: For SI units (nkat/L), multiply result by 16.76.

Expected Values⁵

Male 50-166 U/L (30°C) 80-285 U/L (37°C)

Female 60-132 U/L (30°C) 103-227 U/L (37°C)

Due to a wide range of conditions (dietary, geographical, age, etc.) known to affect reference ranges, it is recommended that each laboratory establish its own reference range.

Performance

1. Assay: 0-1000 U/L. Samples that exceed 1000 U/L should be diluted with an equal volume of saline, re-assayed and results multiplied by two.

2. Correlation: Results obtained with this reagent (y) in 103 samples ranging in LD level from 80 to 540 U/L were compared with those obtained in the same samples using a dry-powder reagent (x) from Pointe Scientific, Inc. based on the same methodology. The correlation coefficient was found to be 0.994 with a regression equation of $y=1.00x + 7.4$ ($Sy.x = 7.95$).
3. Precision: Precision studies were performed following a modification of the guidelines contained in the NCCLS document EP5-T2.¹²

Within Run			Run to Run		
Mean	S.D.	C.V.%	Mean	S.D.	C.V.%
183	2.59	1.4	189	5.53	2.9
441	3.76	0.9	443	6.33	1.4

4. Sensitivity: The sensitivity for the Liquid LD reagent was investigated by reading the change in absorbance at 340nm for a deionized water sample, and serum samples with known LD activities. Ten replicates of each sample were performed. The results of this investigation indicated that on the analyzer used, the Liquid LD reagent showed little or no reagent drift on a zero sample. Under the reaction conditions described, a change in absorbance of 0.0001 was approximately equivalent to 1 U/L of LD activity.

References

1. Tietz, N.W., editor, Fundamentals of Clinical Chemistry, 3rd Ed., W.B. Saunders Co., 391 (1987).
2. Wroblewski, F., LaDue, J.S., Proc. Soc. Exp. Biol. Med. 90:210 (1955).
3. Kubowitz, F., Ott, P., Biochem. 314:94 (1943).
4. Wacker, W.E.C., et al, N. Engl. J. Med. 255:449 (1956).
5. Henry, R.J. et al, Clinical Chemistry; Principles and Technics, 2nd Ed., Hagerstown (MD) Harper & Row, pp. 819-831. (1974).
6. Amador, E., et al, Clin. Chem. 9:391 (1963).
7. Buhl, S.N., et al, Clin. Chem. 23:1289 (1977).
8. Gay, R.J., McComb, R.B., Bowers, G.N., Clinical Chemistry, 2nd Ed., W.B. Saunders Co., 657 (1976).
9. Tietz, N.W., Fundamentals of Clinical Chemistry, 2nd Ed., W.B. Saunders Co., 657,(1976).
10. Kreutzer, H.H., et al, Clin. Chim. Acta 9:64 (1964).
11. NCCLS Document M29-T2, 2nd Ed. (1991).
12. Young, D.S., et al, Clin. Chem., 21:1D (1975).
13. NCCLS Document "Evaluation of Precision Performance of Clinical Chemistry Devices", 2nd Ed. (1992).

Manufactured by Pointe Scientific, Inc.
5449 Research Drive, Canton, MI 48188

"European Authorized Representative"
(O.E.A.R.C.) Av. De Tervueren 34 bte
44 B-1040 Brussels, Belgium



Rev: 5/03 P803-L7572-01